Back to search

Article

The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21

2024-08-19

Abstract excerpt

Obesity is a debilitating disease with increasing worldwide prevalence. Despite its high prevalence, specific pharmacologic intervention for obesity is challenging. Here, we report that halofuginone, an FDA-approved anti-scleroderma and anti-protozoal drug, is a promising anti-obesity agent in rodent models. Halofuginone suppressed food intake, increased energy expenditure, and resulted in weight loss in preclinic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7b72d00b-67ce-53d2-892e-2165b41368d1
DOI
10.1101/2024.08.18.608423
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21DOI 10.1101/2024.08.18.608423
Select a neighboring publication to make it the new centre.